As FDA regulations tighten, report says antimicrobial market headed for a crash

As the FDA continues its effort to phase out antimicrobials, the numbers aren't looking so good for the contracting market. A new report finds not only that growth in 2013 was sluggish, but predicts the North American marketshare will plummet 27%. The markets in Asia and Latin America, however, are forecasted to grow some 6% to 8%--a little bit of light at the end of the tunnel for those investing in emerging markets. The report finds that in 2013, animal health giants Zoetis ($ZTS), Elanco, Merck ($MRK), Merial and Bayer held about 75% of the entire antimicrobial market. More

Suggested Articles

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

Starting next year, drugmakers that market antibiotics for food animals will face tough new FDA rules limiting their use. So now some pharma companies are…

The USDA plans to hold manufacturers of veterinary biotech drugs to new, strict standards on labeling. Although companies will have between four and six years…